Reviews and feature articleBiomarkers for severe eosinophilic asthma
Key words
Abbreviations used
Cited by (0)
This article reports data from studies funded by GlaxoSmithKline.
Disclosure of potential conflict of interest: S. W. Yancey, O. N. Keene, F. C. Albers, H. Ortega, and S. Bates are employees of GlaxoSmithKline and hold stock/shares in GlaxoSmithKline. E. R. Bleecker has performed clinical trials administered by his previous employer, Wake Forest School of Medicine, for AstraZeneca, MedImmune, Boehringer Ingelheim, Pfizer, Cephalon/Teva, Forest, Genentech, GlaxoSmithKline, Johnson & Johnson (Jansen), Novartis, and Sanofi and has also served as a paid consultant for AstraZeneca, MedImmune, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Forest, Novartis, Regeneron, and Sanofi. I. Pavord has received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, and GlaxoSmithKline; received payment for organizing an educational event from AstraZeneca; received advisory board honoraria from Almirall, Genentech, Regeneron, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Schering-Plough, Novartis, Mylan Specialty (Dey Pharma), Napp Pharmaceuticals, and Respivert; and received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and Napp Pharmaceuticals.